ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
1-Year Return
169.78%
This Quarter Return
+23.97%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$71.6M
AUM Growth
-$14.6M
(-17%)
Cap. Flow
-$22.5M
Cap. Flow
% of AUM
-31.35%
Top 10 Holdings %
Top 10 Hldgs %
72.06%
Holding
37
New
3
Increased
6
Reduced
14
Closed
9
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
+$2.62M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$1.77M |
| 3 |
Taysha Gene Therapies
TSHA
|
+$1.12M |
| 4 |
Akero Therapeutics
AKRO
|
+$1.06M |
| 5 |
Terns Pharmaceuticals
TERN
|
+$516K |
Top Sells
| 1 |
Insmed
INSM
|
+$6.94M |
| 2 |
Enliven Therapeutics
ELVN
|
+$5.22M |
| 3 |
Tourmaline Bio
TRML
|
+$2.29M |
| 4 |
Merck
MRK
|
+$2.06M |
| 5 |
Ocular Therapeutix
OCUL
|
+$1.9M |
Sector Composition
| 1 | Healthcare | 99.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ocular Therapeutix
OCUL
$2.23B
| $9.42M | 13.15% |
1,014,940
-204,784
| -17% | -$1.9M |
|
|
2
Cidara Therapeutics
CDTX
$1.66B
| $8.75M | 12.21% |
179,569
+53,861
| +43% | +$2.62M |
|
|
WHWK
3
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$93.8M
| $6.38M | 8.9% |
3,410,402
| – | – |
|
4
Soleno Therapeutics
SLNO
$2.85B
| $5.31M | 7.42% |
63,436
-3,700
| -6% | -$310K |
|
|
5
Tourmaline Bio
TRML
$1.22B
| $4.54M | 6.33% |
283,682
-143,200
| -34% | -$2.29M |
|
6
Ascendis Pharma
ASND
$11.8B
| $3.9M | 5.44% |
22,576
-764
| -3% | -$132K |
|
|
7
Insmed
INSM
$30.8B
| $3.73M | 5.21% |
37,070
-69,004
| -65% | -$6.94M |
|
8
argenx
ARGX
$46.3B
| $3.69M | 5.16% |
6,702
-321
| -5% | -$177K |
|
9
Praxis Precision Medicines
PRAX
$794M
| $3.12M | 4.35% |
74,087
-13,054
| -15% | -$549K |
|
|
10
Jazz Pharmaceuticals
JAZZ
$7.65B
| $2.79M | 3.89% |
26,283
+16,708
| +174% | +$1.77M |
|
11
Trevi Therapeutics
TRVI
$1B
| $2.7M | 3.77% |
493,735
-292,226
| -37% | -$1.6M |
|
12
Oculis Holding
OCS
$911M
| $2.07M | 2.89% |
106,718
-18,282
| -15% | -$355K |
|
13
Revolution Medicines
RVMD
$8.7B
| $2.05M | 2.86% |
55,693
-10,969
| -16% | -$404K |
|
|
BBOT
14
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$823M
| $1.99M | 2.78% |
187,257
| – | – |
|
|
15
Terns Pharmaceuticals
TERN
$633M
| $1.73M | 2.42% |
463,864
+138,314
| +42% | +$516K |
|
16
Surrozen
SRZN
$99.1M
| $1.52M | 2.12% |
170,000
| – | – |
|
|
DRUG
17
Bright Minds Biosciences
DRUG
$346M
| $1.27M | 1.77% |
48,474
-11,274
| -19% | -$294K |
|
|
18
Taysha Gene Therapies
TSHA
$837M
| $1.12M | 1.57% |
+485,669
| New | +$1.12M |
|
|
19
Akero Therapeutics
AKRO
$3.48B
| $1.06M | 1.47% |
+19,772
| New | +$1.06M |
|
20
Zymeworks
ZYME
$1.19B
| $1.05M | 1.47% |
83,655
+15,196
| +22% | +$191K |
|
21
Liquidia Corp
LQDA
$2.24B
| $945K | 1.32% |
75,876
-77,606
| -51% | -$967K |
|
22
Ultragenyx Pharmaceutical
RARE
$2.92B
| $866K | 1.21% |
23,814
+2,524
| +12% | +$91.8K |
|
23
Verastem
VSTM
$598M
| $624K | 0.87% |
150,414
-25,586
| -15% | -$106K |
|
24
Fulcrum Therapeutics
FULC
$379M
| $410K | 0.57% |
+59,650
| New | +$410K |
|
25
Unicycive Therapeutics
UNCY
$68.4M
| $300K | 0.42% |
62,899
-172,390
| -73% | -$822K |
|